Where Will Cerebras Stock be in 3 Years?

Cerebras Systems reported Q1 2026 revenue of $191.3 million, up 92% year over year, and guided for $194 million in current-quarter revenue and $860 million for full-year 2026, but that outlook implies a slowdown from recent growth rates. Investors are focused on valuation at 65x sales and gross margin pressure, with full-year non-GAAP gross margin expected at 38% to 41% versus 47% in Q1. Analysts remain constructive, with a 12-month median price target of $300, implying about 65% upside, but the stock has already fallen 41% from its post-IPO peak.

Analysis

The market is treating this as a classic post-IPO multiple reset, but the deeper issue is whether Cerebras can convert backlog into self-funded capacity fast enough to stop the business from looking artificially asset-light. If it keeps renting systems to fulfill demand, reported gross margin will stay suppressed and the equity will trade like a capital-hungry infrastructure provider rather than a high-margin software/platform story. The real inflection is not this quarter’s growth rate; it is whether management can show that incremental capacity comes online without another step-down in margin or a working-capital drag.

Second-order, the winners here are the adjacent infrastructure names that can monetize the AI inference buildout without single-name execution risk. Amazon benefits if Cerebras helps make inference cheaper on AWS, because lower cost per token expands usage and improves cloud consumption elasticity; Nvidia is less threatened near-term than the headline suggests because the demand expansion for inference can outpace share shifts, but any credible alternative architecture does pressure pricing power at the margin. Broadcom is a more subtle beneficiary if hyperscalers continue diversifying compute supply, since custom silicon budgets tend to broaden rather than disappear.

The contrarian view is that the current selloff may be underpricing the convexity of a very large backlog paired with a tiny current revenue base. If execution is merely good, not perfect, the stock can rerate violently because a modest absolute improvement in capacity has a large percentage impact on revenue inflection over the next 12-24 months. The bear case is that valuation compresses faster than growth reaccelerates, especially if investors conclude the path to 2027-2028 is capital intensive and slower than the market is modeling.

Key Decisions for Investors

• Avoid chasing the tape in CBRS common stock until management proves margin stabilization; wait for either a second-quarter capacity update or a post-earnings base, because the next leg is more likely to be driven by operating evidence than by backlog optics.
• Express a relative-value long AMZN / short CBRS pair for the next 3-6 months: AWS should capture inference demand with lower single-name execution risk, while CBRS still has to prove it can scale capacity without further gross-margin compression.
• Buy NVDA on weakness rather than fade it; if inference spend broadens as expected, Nvidia remains the primary liquidity recipient even if alternative chips gain share. Use a 6-12 month horizon and keep sizing modest, since the risk is valuation sensitivity rather than fundamental deterioration.
• For higher-risk portfolios, consider CBRS call spreads 9-15 months out instead of outright equity: the thesis needs a capacity inflection, and defined-risk upside is preferable given the high sales multiple and binary execution timeline.
• Set a trigger to add to CBRS only if full-year margin guidance stops deteriorating or data-center capacity adds are explicitly quantified; absent that, the stock is a momentum trade, not a fundamentals trade.